Ruxolitinib for treating polycythaemia vera: a single technology appraisal
Ruxolitinib for treating polycythaemia vera: a single technology appraisal
This report is a critique of the company’s submission (CS) to NICE from Novartis on the clinical effectiveness and cost effectiveness of ruxolitinib for treating polycythaemia vera (PV). It identifies the strengths and weaknesses of the CS.
National Institute for Health and Care Research
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Woods, Lois
8149aa11-7664-4052-a18b-98f7bde83180
Hawa, Asyl
64ce4257-6176-4a4e-bce5-5e1147377355
Scott, David Alexander
19b5fd34-9974-4ae4-8be0-27a693639e20
Frampton, Geoff
26c6163c-3428-45b8-b8b9-92091ff6c69f
May 2022
Lord, Joanne
fd3b2bf0-9403-466a-8184-9303bdc80a9a
Woods, Lois
8149aa11-7664-4052-a18b-98f7bde83180
Hawa, Asyl
64ce4257-6176-4a4e-bce5-5e1147377355
Scott, David Alexander
19b5fd34-9974-4ae4-8be0-27a693639e20
Frampton, Geoff
26c6163c-3428-45b8-b8b9-92091ff6c69f
Lord, Joanne, Woods, Lois, Hawa, Asyl, Scott, David Alexander and Frampton, Geoff
(2022)
Ruxolitinib for treating polycythaemia vera: a single technology appraisal
(Health Technology Assessment)
National Institute for Health and Care Research
140pp.
Record type:
Monograph
(Project Report)
Abstract
This report is a critique of the company’s submission (CS) to NICE from Novartis on the clinical effectiveness and cost effectiveness of ruxolitinib for treating polycythaemia vera (PV). It identifies the strengths and weaknesses of the CS.
Text
Ruxolitinib ID5106 EAG Report
- Other
Available under License Other.
More information
Published date: May 2022
Identifiers
Local EPrints ID: 484727
URI: http://eprints.soton.ac.uk/id/eprint/484727
PURE UUID: 78e4503d-6c13-4cab-bdf0-cac74da2f75a
Catalogue record
Date deposited: 20 Nov 2023 17:51
Last modified: 11 Sep 2024 02:26
Export record
Contributors
Author:
David Alexander Scott
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics